434 related articles for article (PubMed ID: 30611722)
1. NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF.
Daubert MA; Adams K; Yow E; Barnhart HX; Douglas PS; Rimmer S; Norris C; Cooper L; Leifer E; Desvigne-Nickens P; Anstrom K; Fiuzat M; Ezekowitz J; Mark DB; O'Connor CM; Januzzi J; Felker GM
JACC Heart Fail; 2019 Feb; 7(2):158-168. PubMed ID: 30611722
[TBL] [Abstract][Full Text] [Related]
2. Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
Felker GM; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Januzzi JL; Mark DB; Piña IL; Passmore G; Whellan DJ; Yang H; Cooper LS; Leifer ES; Desvigne-Nickens P; O'Connor CM
JAMA; 2017 Aug; 318(8):713-720. PubMed ID: 28829876
[TBL] [Abstract][Full Text] [Related]
3. Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction.
Januzzi JL; Ahmad T; Mulder H; Coles A; Anstrom KJ; Adams KF; Ezekowitz JA; Fiuzat M; Houston-Miller N; Mark DB; Piña IL; Passmore G; Whellan DJ; Cooper LS; Leifer ES; Desvigne-Nickens P; Felker GM; O'Connor CM
J Am Coll Cardiol; 2019 Sep; 74(9):1205-1217. PubMed ID: 31466618
[TBL] [Abstract][Full Text] [Related]
4. Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction.
Daubert MA; Yow E; Barnhart HX; Piña IL; Ahmad T; Leifer E; Cooper L; Desvigne-Nickens P; Fiuzat M; Adams K; Ezekowitz J; Whellan DJ; Januzzi JL; O'Connor CM; Felker GM
J Am Heart Assoc; 2021 May; 10(10):e019712. PubMed ID: 33955231
[TBL] [Abstract][Full Text] [Related]
5. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
[TBL] [Abstract][Full Text] [Related]
7. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.
Januzzi JL; Rehman SU; Mohammed AA; Bhardwaj A; Barajas L; Barajas J; Kim HN; Baggish AL; Weiner RB; Chen-Tournoux A; Marshall JE; Moore SA; Carlson WD; Lewis GD; Shin J; Sullivan D; Parks K; Wang TJ; Gregory SA; Uthamalingam S; Semigran MJ
J Am Coll Cardiol; 2011 Oct; 58(18):1881-9. PubMed ID: 22018299
[TBL] [Abstract][Full Text] [Related]
8. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF).
Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP;
Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728
[TBL] [Abstract][Full Text] [Related]
9. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
Ezekowitz JA; O'Connor CM; Troughton RW; Alemayehu WG; Westerhout CM; Voors AA; Butler J; Lam CSP; Ponikowski P; Emdin M; Patel MJ; Pieske B; Roessig L; Hernandez AF; Armstrong PW
JACC Heart Fail; 2020 Nov; 8(11):931-939. PubMed ID: 33039447
[TBL] [Abstract][Full Text] [Related]
10. Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction.
Salah K; Stienen S; Pinto YM; Eurlings LW; Metra M; Bayes-Genis A; Verdiani V; Tijssen JGP; Kok WE
Heart; 2019 Aug; 105(15):1182-1189. PubMed ID: 30962192
[TBL] [Abstract][Full Text] [Related]
11. Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial.
Parcha V; Patel N; Kalra R; Suri SS; Arora G; Wang TJ; Arora P
J Am Heart Assoc; 2021 Apr; 10(7):e018689. PubMed ID: 33754794
[TBL] [Abstract][Full Text] [Related]
12. Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: a retrospective cross-sectional study.
Nah EH; Kim SY; Cho S; Kim S; Cho HI
BMJ Open; 2019 Apr; 9(4):e026030. PubMed ID: 31005928
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal evaluation of ventricular ejection fraction and NT-proBNP across heart failure subgroups.
Martinsson A; Oest P; Wiborg MB; Reitan Ö; Smith JG
Scand Cardiovasc J; 2018 Aug; 52(4):205-210. PubMed ID: 29656687
[TBL] [Abstract][Full Text] [Related]
14. Serial measurements of serum NT-proBNP as markers of left ventricular systolic function and remodeling in children with heart failure.
Rusconi PG; Ludwig DA; Ratnasamy C; Mas R; Harmon WG; Colan SD; Lipshultz SE
Am Heart J; 2010 Oct; 160(4):776-83. PubMed ID: 20934575
[TBL] [Abstract][Full Text] [Related]
15. Improvement in left ventricular ejection fraction and reverse remodeling in elderly heart failure patients on intense NT-proBNP-guided therapy.
Kaufmann BA; Goetschalckx K; Min SY; Maeder MT; Bucher U; Nietlispach F; Bernheim AM; Pfisterer ME; Brunner-La Rocca HP;
Int J Cardiol; 2015 Jul; 191():286-93. PubMed ID: 25981371
[TBL] [Abstract][Full Text] [Related]
16. The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study.
Ibrahim NE; Januzzi JL
Curr Heart Fail Rep; 2018 Apr; 15(2):37-43. PubMed ID: 29468530
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction.
Huang A; Qi X; Hou W; Qi Y; Zhao N; Liu K
Acta Cardiol; 2018 Feb; 73(1):41-48. PubMed ID: 28944719
[TBL] [Abstract][Full Text] [Related]
18. N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum.
Faxén UL; Lund LH; Orsini N; Strömberg A; Andersson DC; Linde C; Dahlström U; Savarese G
Int J Cardiol; 2019 Jul; 287():66-72. PubMed ID: 31005415
[TBL] [Abstract][Full Text] [Related]
19. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study.
Weiner RB; Baggish AL; Chen-Tournoux A; Marshall JE; Gaggin HK; Bhardwaj A; Mohammed AA; Rehman SU; Barajas L; Barajas J; Gregory SA; Moore SA; Semigran MJ; Januzzi JL
Eur J Heart Fail; 2013 Mar; 15(3):342-51. PubMed ID: 23132825
[TBL] [Abstract][Full Text] [Related]
20. N-terminal pro-B-type natriuretic peptide as a diagnostic test for ventricular dysfunction in patients with coronary disease: data from the heart and soul study.
Corteville DC; Bibbins-Domingo K; Wu AH; Ali S; Schiller NB; Whooley MA
Arch Intern Med; 2007 Mar; 167(5):483-9. PubMed ID: 17353496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
